Research paperPharmacokinetics and tissue distribution of adriamycin and adriamycinol after intravenous administration of adriamycin-loaded neutral proliposomes to rats
References (31)
- et al.
Analysis of adriamycin and adriamycinol in micro volumes of rat plasma
J. Chromatogr.
(1983) New calculation method for mean apparent drug volume of distribution and application to rationale dosage regimens
J. Pharm. Sci.
(1979)- et al.
Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit
Biochem. Pharmacol.
(1987) - et al.
Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing negatively charged liposomes to rats
Int. J. Pharm.
(1994) - et al.
Characterization of proliposome
J. Pharm. Sci.
(1986) - et al.
Proliposomes: A novel solution to an old problem
J. Pharm. Sci.
(1986) - et al.
Preparation and evaluation of proliposomes containing propranolol hydrochloride
J. Microencapsul.
(1995) - et al.
Proliposome as an intranasal dosage form for the sustained delivery of propranolol
J. Controlled Release
(1995) - et al.
Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing neutral liposomes to rats
J. Clin. Pharm. Ther.
(1993) Pharmacokinetic drug interactions of commonly used anticancer drugs
Clin. Pharmacokinet.
(1986)
Evidence of possible dose-dependent doxorubicin plasma kinetics in man
Cancer Treat. Rep.
Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
J. Pharmacokinet. Biopharm.
Stability testing of liposomes during storage
Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
Cancer Res.
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin
Br. J. Cancer
Cited by (23)
Nanoliposomes in polymeric granules: Novel process strategy to produce stable and versatile delivery systems
2020, Journal of Drug Delivery Science and TechnologyCitation Excerpt :Liposomes stabilization for promoting their use in solid particulate dosage forms can be performed by several methods, such as melt-granulation, adsorption on solid support, spray-cooling, spray-drying, melt-extrusion/spheronization, freeze-pelletization, pastillation [7]. Moreover, Payne et al. [8] and Mayer et al. [9] introduced the concept of proliposomes, free-flowing particles made of water soluble porous powder - also based on polymeric compounds - and lipid components, structures with a better stability [10–15]. However, many proliposomes formulations are available as powder forms with poor technological properties and, thus, difficult to handle [16].
Some approaches to large-scale manufacturing of liposomes
2014, Emerging Nanotechnologies for ManufacturingThe suppressed expression and functional activity of hepatic P-glycoprotein in rats with protein-calorie malnutrition
2003, Journal of Pharmaceutical SciencesCitation Excerpt :The in vivo canalicular clearance (CLexc) was calculated by dividing the biliary excretion rate of daunomycin by the liver concentration of daunomycin at the steady state. The concentrations of daunomycin in plasma, liver (homogenates), and bile samples were quantified by HPLC.11 A 100-μL aliquot of the biological samples (i.e., plasma, bile, and supernatants of the liver homogenates) was deproteinized by the addition of MeOH (250 μL) containing adriamycin (internal standard, 1 μM).
Preparation and evaluation of proliposomes containing salmon calcitonin
2002, Journal of Controlled ReleaseSuppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases
2000, Journal of Biological ChemistryCitation Excerpt :Because the purity of the cultures was about 95% myocytes, as determined by an immunocytochemical assay using an anti-cardiac α-sarcomeric actin antibody (19), the majority of the apoptotic cells then represents cardiomyocytes. On the other hand, the range of DOX concentrations (0.1–1.0 μm) used to treat these cultured cells were within the levels accumulated in the myocardium of Syrian hamsters between 15 and 60 min after DOX treatmentin vivo at a single intravenous dose of 5 mg/kg (30) and in the myocardium of rats 30 min after intravenous infusion of DOX at 16 mg/kg (31). Therefore, these results obtained from the cultured neonatal mouse cardiomyocytes clearly demonstrated that cardiomyocytes exposed to in vivo pharmacologically comparable exposure levels of DOX undergo apoptosis and that this mode of cell death would contribute remarkably to the total loss of cardiomyocytes in the DOX-treated myocardium.